On November 23, 2016, Opexa Therapeutics, Inc. (the “Company”) received notice from Ares Trading S.A. (“Merck Serono”), a wholly owned subsidiary of Merck Serono S.A., that Merck Serono would not be exercising its option (the “Option”) to acquire the exclusive, worldwide (excluding Japan) license to the Company’s Tcelna program for the treatment of multiple sclerosis (“MS”) granted to Merck Serono under the Option and License Agreement dated February4, 2013, as amended, by and between the Company and Merck Serono (the “Agreement”). As a result of receiving the notice from Merck Serono, the Agreement automatically expired upon receipt. As previously announced on October 28, 2016, the Company’s Phase IIb Abili-T clinical trial designed to evaluate the efficacy and safety of Tcelna (imilecleucel-T) in patients with secondary progressive MS did not meet its primary or secondary endpoints.
About OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company’s product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient’s immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.
OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) Recent Trading Information OPEXA THERAPEUTICS, INC. (NASDAQ:OPXA) closed its last trading session down -0.143 at 0.907 with 1,290,466 shares trading hands.
Related
